Event Information

Time: July 29, 2015 (Wednesday)

Place: TRPMA Conference Room

TRPMA had the pleasure to invite the CEO of Fountain Medical Development Ltd. in China to share the first-hand knowledge about the new drug registration and clinical trial regulations in China.

Mr Dan Chang, the CEO of Fountain, analysed the 11th 5-year plan and the 12th 5-year plan in China, and introduced the 13th 5-year plan. The key word for the 13th 5-year plan is “breakthrough”. It will focus on the development of breakthrough therapeutic treatments and products for unmet medical needs (e.g. orphan drugs), as well as the advances of innovative technology.

Mr Lei-Guo Hsu, Vice Director of the International Integration Department of Fountain, also talked about the strategies and opportunities for joint new drug R&D in Taiwan, China and the US. He briefed the audience on the possible strategies for applying for IND in China.

Finally, Mr Chang answered questions raised by the audience. He suggested that the biopharmaceutical companies in Taiwan should seize the opportunity and take on the market in China with effective strategies.